Biopharmaceutical innovation is powering a rapid pace of medical breakthroughs and scientific advancements. America’s biopharmaceutical companies are working day in and day out to uncover new targets, treatments and ultimately cures for patients’ lives.
But despite this steady stream of progress, there is still much left to learn about arguably one of the most important areas of medicine – the brain, and the diseases that impact it. Alzheimer's, multiple sclerosis and other neurological diseases and disorders affect one in six people around the world, driving a demand for innovative solutions to complex illnesses.
In order to jumpstart a dialogue on the many complex issues impacting the brain – from the diseases which affect it to the social dynamics that influence it – PhRMA is bringing together industry thought leaders, researchers and scientists in Los Angeles for a conversation titled “The Brain: The Next Frontier.”
We’ll hear from those at the helm of research and innovation, from biopharmaceuticals to brain machine interfaces. Dr. Eric Siemers, senior medical director, Alzheimer's Global Development Team at Eli Lilly and Co., who currently directs late stage clinical research efforts concerning investigational treatments for Alzheimer’s disease, will speak on a panel that examines the current state of treatments to combat neurological disorders. Dr. Siemers’ additional research areas include the use of biomarkers in investigational drug research and the development of clinical trial designs that broadly characterize the effects of investigational drugs on chronic diseases.
Other leaders in the scientific community will discuss the state of research and treatments available, and how the brain processes and perceives information. The entire discussion will be led by Axios’ Science editor, Alison Snyder.
This discussion will be live-streamed here on Wednesday, June 14, beginning at 8:30 a.m. PST.